Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740951 | 0.88 | TDP1 (0.52) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL1414035 | 0.86 | ATM (0.58) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL27780316 | 0.83 | TDP1 (0.55) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL311445 | 0.83 | ATM (0.55) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL17870695 | 0.83 | TDP1 (0.59) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL5194061 | 0.83 | TDP1 (0.55) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL26803674 | 0.81 | ATM (0.49) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL9477777 | 0.81 | BACE1 (0.47) | SNCAALDH1A1TSHRCYP1A2L3MBTL1 | |
| SCHEMBL310839 | 0.80 | TDP1 (0.60) | ATMTDP1SNCAALDH1A1MAPT | |
| SCHEMBL29362511 | 0.80 | TDP1 (0.60) | ATMTDP1SNCAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BEONE MEDICINES I GMBH (CH) | 2024-07-25 | — | — | US | disclosed |
| CN-116981675-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| US-20050154230-A1 | Urea derivatives | BAYER HEALTHCARE AG (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1461311-A2 | UREA DERIVATIVES AS VR1-ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003055848-A2 | UREA DERIVATIVES AS VR1- ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154230-A1 | Urea derivatives | SLC14A1, UBA1, VAT1 | ATM 3474/4885TDP1 1125/4885SNCA 1714/4885 |
| US-20240246977-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE | BTK, CBL, SYK | ATM 1075/4885TDP1 1237/4885SNCA 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.